SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND PRACTICES (Details Narrative) |
6 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Oct. 10, 2025
¥ / shares
shares
|
May 01, 2025
USD ($)
|
May 01, 2025
JPY (¥)
|
Jun. 30, 2026
USD ($)
shares
|
Jun. 30, 2026
JPY (¥)
shares
|
Jun. 30, 2025
JPY (¥)
shares
|
Dec. 31, 2025
JPY (¥)
|
Jun. 30, 2026
JPY (¥)
|
|
| Product Information [Line Items] | ||||||||
| Foreign currency transactions | Translations of amounts in the unaudited interim condensed consolidated balance sheets, unaudited interim condensed consolidated statements of income, and unaudited interim condensed consolidated statements of cash flows from JPY into US$ as of and for the six months ended June 30, 2026 are solely for the convenience of the reader and were calculated at the noon buying rate of US$1 = JPY162.61, as published in H.10 statistical release of the United States Federal Reserve Board. No representation is made that the JPY amounts could have been, or could be, converted, realized, or settled into US$ at such rate or at any other rate. | Translations of amounts in the unaudited interim condensed consolidated balance sheets, unaudited interim condensed consolidated statements of income, and unaudited interim condensed consolidated statements of cash flows from JPY into US$ as of and for the six months ended June 30, 2026 are solely for the convenience of the reader and were calculated at the noon buying rate of US$1 = JPY162.61, as published in H.10 statistical release of the United States Federal Reserve Board. No representation is made that the JPY amounts could have been, or could be, converted, realized, or settled into US$ at such rate or at any other rate. | ||||||
| Cash | ¥ 0 | ¥ 0 | ||||||
| Cash | 20,500,000 | |||||||
| Allowance for credit losses of accounts receivable | $ 40,300 | ¥ 6,553,222 | 7,405,870 | |||||
| Total deferred expenses | 142,111 | 22,177,409 | 23,108,750 | |||||
| Impairment of long-lived assets | 0 | ¥ 0 | ||||||
| Deferred offering costs | 1,908,972 | ¥ 303,679,188 | ||||||
| Registration fees | 204,348 | 33,229,082 | ¥ 32,516,324 | |||||
| Advertising expenses | 1,420,270 | 230,950,049 | 66,105,459 | |||||
| Grant income | $ 106,453 | ¥ 17,310,392 | ¥ 9,399,558 | |||||
| Dilutive shares | shares | 3,000 | 3,000 | 3,000 | |||||
| Accounts Receivable [Member] | Customer Concentration Risk [Member] | No Customer [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 10.00% | 10.00% | 10.00% | |||||
| Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 10.68% | 10.68% | 10.00% | |||||
| Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Vendor [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 10.00% | 10.00% | ||||||
| Accounts Payable [Member] | Customer Concentration Risk [Member] | A Vendor [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 19.80% | 19.80% | 21.60% | |||||
| Accounts Payable [Member] | Customer Concentration Risk [Member] | B Vendor [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 10.10% | |||||||
| Accounts Payable [Member] | Customer Concentration Risk [Member] | C Vendor [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Concentration risk percentage | 13.30% | 13.30% | ||||||
| IPO [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Sale of units in initial public offering | shares | 1,250,000 | |||||||
| Sale of units per share | ¥ / shares | ¥ 4.00 | |||||||
| Private Placement [Member] | ||||||||
| Product Information [Line Items] | ||||||||
| Net proceeds | $ 4,302,198 | ¥ 658,666,480 | ||||||